291 related articles for article (PubMed ID: 24100880)
1. Pipeline of drugs for related diseases: tuberculosis.
Dooley KE; Nuermberger EL; Diacon AH
Curr Opin HIV AIDS; 2013 Nov; 8(6):579-85. PubMed ID: 24100880
[TBL] [Abstract][Full Text] [Related]
2. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
3. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
[TBL] [Abstract][Full Text] [Related]
4. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
5. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes.
Lienhardt C; Vernon A; Raviglione MC
Curr Opin Pulm Med; 2010 May; 16(3):186-93. PubMed ID: 20216421
[TBL] [Abstract][Full Text] [Related]
6. Tuberculosis: clinical trials and new drug regimens.
Kwon YS; Jeong BH; Koh WJ
Curr Opin Pulm Med; 2014 May; 20(3):280-6. PubMed ID: 24614239
[TBL] [Abstract][Full Text] [Related]
7. The tuberculosis drug discovery and development pipeline and emerging drug targets.
Mdluli K; Kaneko T; Upton A
Cold Spring Harb Perspect Med; 2015 Jan; 5(6):. PubMed ID: 25635061
[TBL] [Abstract][Full Text] [Related]
8. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
9. Tuberculosis: current treatment, diagnostics, and newer antitubercular agents in clinical trials.
Ahsan MJ; Ansari MY; Yasmin S; Jadav SS; Kumar P; Garg SK; Aseri A; Khalilullah H
Infect Disord Drug Targets; 2015; 15(1):32-41. PubMed ID: 25246035
[TBL] [Abstract][Full Text] [Related]
10. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
Kwon YS; Jeong BH; Koh WJ
Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
[TBL] [Abstract][Full Text] [Related]
11. Shortened tuberculosis treatment regimens: what is new?
Silva DR; Mello FCQ; Migliori GB
J Bras Pneumol; 2020; 46(2):e20200009. PubMed ID: 32215450
[TBL] [Abstract][Full Text] [Related]
12. Delamanid Kills Dormant Mycobacteria
Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
[TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
15. Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy.
Sgaragli G; Frosini M; Saponara S; Corelli F
Curr Med Chem; 2016; 23(21):2245-74. PubMed ID: 27142291
[TBL] [Abstract][Full Text] [Related]
16. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).
Lupien A; Vocat A; Foo CS; Blattes E; Gillon JY; Makarov V; Cole ST
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126954
[TBL] [Abstract][Full Text] [Related]
17. [Present and future in the use of anti-tubercular drugs].
Didilescu C; Craiova UM
Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168
[TBL] [Abstract][Full Text] [Related]
18. Advances in the development of new tuberculosis drugs and treatment regimens.
Zumla A; Nahid P; Cole ST
Nat Rev Drug Discov; 2013 May; 12(5):388-404. PubMed ID: 23629506
[TBL] [Abstract][Full Text] [Related]
19. Bedaquiline and delamanid in tuberculosis.
Esposito S; Bianchini S; Blasi F
Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
[TBL] [Abstract][Full Text] [Related]
20. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
